Logo

Alex Therapeutics Reports Results for Almee Under Clinical Evaluation for the Treatment of Anxiety Associated with Pulmonary Fibrosis (PF)

Share this
Alex Therapeutics

Alex Therapeutics Reports Results for Almee Under Clinical Evaluation for the Treatment of Anxiety Associated with Pulmonary Fibrosis (PF)

Shots:

  • The (COMPANION) clinical trial evaluated the efficacy of Almee, a 9wk. digital CBT intervention accessed through a smartphone or tablet, in patients (n=108) suffering from anxiety due to PF across the US
  • The study met its 1EP of change from baseline in GAD-7 anxiety scores by depicting a 2.7-point improvement vs control thereby demonstrating significant efficacy results in reducing anxiety. Moreover, the study also depicted an improvement in QoL by 4.4 points vs control & in K-BILD psychological domain by 6.5 points
  • Almee is an app jointly developed by Alex Therapeutics and its partner Vicore Pharma to offer personalized treatment for anxiety based on cognitive behavioral therapy (CBT)

Ref: Alex Therapeutics | Image: Alex Therapeutics

Related News:- Vistagen Reports P-III Trial (PALISADE-2) Results of Fasedienol (PH94B) Nasal Spray for Social Anxiety Disorder

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions